EquityZen Growth Technology Fund LLC - Series 925
Raised
$500K
Investors
23
Min Invest
$10,001
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 925 is a Delaware LLC filed by EquityZen Advisors on 2021-08-17, raising $500K from 23 investors under Rule 506(b) and Section 3(c)(1). Minimum investment is $10K. This is part of the EquityZen platform, which operates 1889+ related pre-IPO investment vehicles focused on secondary market opportunities in private growth companies.
This pre-IPO pooled investment fund uses the standard 506(b)/3(c)(1) exemption pattern common to private secondary market platforms. The $10K minimum investment represents an accessible entry point relative to traditional private equity vehicles, consistent with EquityZen's retail-plus investor model for fractional exposure to late-stage private companies.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Richard Thoms
Executive Officer · Salt Lake City, UT
Assure Fund Management II LLC
Director · Salt Lake City, UT
Philip Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
